10-Q: Celularity Inc. Reports Third Quarter 2024 Results Amidst Financial Challenges

Celularity Inc. reports a significant increase in revenue for the third quarter of 2024, but continues to face substantial financial challenges and going concern uncertainties.

Summary

• Celularity Inc. reported a net loss of $16.1 million for the third quarter of 2024, and a net loss of $44.6 million for the nine months ended September 30, 2024.
• The company's total net revenues for the third quarter of 2024 were $9.3 million, a 145.5% increase compared to the same period in 2023, driven by growth in product sales and license revenues.
• Operating expenses decreased significantly to $20.8 million in the third quarter of 2024, compared to $103 million in the same period of 2023, primarily due to lower research and development costs and the absence of goodwill impairment charges.
• The company's cash and cash equivalents, including restricted cash, totaled $10.3 million as of September 30, 2024.
• Celularity has an accumulated deficit of $886.4 million as of September 30, 2024, and faces substantial doubt about its ability to continue as a going concern.
• The company has approximately $46.1 million of debt outstanding, all of which is currently due or due within one year of the issuance date of the report.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with strong revenue growth offset by significant losses, debt, and going concern issues. The overall sentiment is negative due to the financial instability and uncertainty surrounding the company's future.

Positives

• The company experienced a significant increase in total net revenues, driven by growth in product sales and license revenues.
• Operating expenses decreased substantially, primarily due to lower research and development costs and the absence of goodwill impairment charges.
• The company successfully acquired Rebound through an asset purchase agreement with Sequence LifeScience, Inc.

Negatives

• The company continues to incur significant operating losses and has an accumulated deficit of $886.4 million.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a significant amount of debt outstanding, all of which is currently due or due within one year of the issuance date of the report.
• The company has not yet filed a registration statement with the SEC for the resale by Yorkville of the shares of common stock issued under the SEPA, which is deemed an event of default under the SEPA.

Risks

• The company's ability to continue as a going concern is uncertain due to significant operating losses and the need for additional capital.
• Failure to obtain additional funding may force the company to curtail operations, liquidate assets, or seek bankruptcy protection.
• The company's debt obligations could lead to lenders seizing assets or forcing liquidation if not repaid.
• The company's securities may be delisted from Nasdaq if it fails to regain compliance with listing requirements.
• The company's reliance on third parties for clinical trials and distribution arrangements poses risks to its operations.
• The company's therapeutic candidates may not receive regulatory approval or may cause undesirable side effects.
• The company faces significant competition from other biotechnology and pharmaceutical companies.

Future Outlook

The company expects to continue to incur significant operating losses and use net cash for operations for the foreseeable future. The company will need to secure additional sources of outside capital to fund its investments. The company is exploring licensing and collaboration arrangements for its cellular therapeutics as well as distribution arrangements for its degenerative disease business.

Management Comments

• Management can provide no assurance that the company's research and development and commercialization efforts will be successfully completed, or that adequate protection of the company's intellectual property will be adequately maintained.
• Management can provide no assurance that the company will be able to secure additional outside capital in the future or on terms that are acceptable to the company.
• Management will be required to seek other strategic alternatives, which may include, among others, a significant curtailment of the company's operations, a sale of certain of the company's assets, a sale of the entire company to strategic or financial investors, and/or allowing the company to become insolvent by filing for bankruptcy protection under the provisions of the U.S. Bankruptcy Code.

Industry Context

The company operates in the competitive biotechnology and pharmaceutical industries, facing challenges from other companies developing similar therapies and products. The company's focus on placental-derived allogeneic cells is a novel approach, but it also creates significant challenges in terms of regulatory approval and commercialization.

Comparison to Industry Standards

• The company's revenue growth of 145.5% in the third quarter of 2024 is significant compared to many other biotech companies, but it is important to note that this growth is from a relatively low base.
• The company's operating expenses decreased by 79.8% in the third quarter of 2024, which is a positive sign, but it is important to note that this decrease is primarily due to lower research and development costs, which may impact future growth.
• The company's net loss of $16.1 million in the third quarter of 2024 is still substantial, and it is important to note that the company has an accumulated deficit of $886.4 million.
• The company's cash and cash equivalents of $10.3 million as of September 30, 2024, is relatively low compared to other biotech companies, and it is important to note that the company has substantial debt obligations.
• The company's going concern uncertainty is a significant risk, and it is important to note that many other biotech companies do not face this level of uncertainty.

Legal Proceedings

• The company is cooperating with a Civil Investigative Demand from the U.S. Attorneys Office for the Eastern District of Pennsylvania.
• The company is involved in a legal dispute with Evolution Biologyx, LLC, et al.
• The company entered into a settlement agreement and mutual release with TCWGlobal.

Related Party Transactions

• The company has a loan agreement with its Chairman and Chief Executive Officer, Dr. Robert Hariri.
• The company has a distribution agreement with Genting Innovation PTE LTD, a related party.
• The company has a Technology Services Agreement with Fountain Life Management LLC, a related party.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be affected by potential workforce reductions or changes in the company's operations.
• Customers may be impacted by potential disruptions in the supply of the company's products.
• Suppliers and creditors face the risk of non-payment due to the company's financial challenges.

Next Steps

• The company needs to secure additional outside capital to fund its operations.
• The company needs to regain compliance with Nasdaq listing requirements.
• The company needs to continue to explore licensing and collaboration arrangements for its cellular therapeutics.
• The company needs to continue to develop and commercialize its biomaterials products.

Key Dates

Keywords

Cell Therapy, Regenerative Medicine, Biomaterials, Placental-Derived, Clinical Trials, Biobanking, Debt Financing, Going Concern, Operating Losses, Warrant Liabilities